Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib (original) (raw)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, John Kirkwood
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009
View PDFchevron_right
A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
Anna Pavlick
PLoS ONE, 2010
View PDFchevron_right
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort
Ana Carneiro
British Journal of Dermatology, 2013
View PDFchevron_right
Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Ruifeng Yang
Clinical Cancer Research, 2013
View PDFchevron_right
Concordance of somatic mutation profiles [BRAF, NRAS and TERT] and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples
Dominick A Leone
Human pathology, 2018
View PDFchevron_right
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Lawrence Flaherty
Journal of Clinical Oncology, 2013
View PDFchevron_right
BRAF Mutations in Metastatic Melanoma A Possible Association with Clinical Outcome
Sabrina Angelini
Clinical Cancer Research, 2003
View PDFchevron_right
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
Gabriella Brancaccio
Therapeutic Advances in Medical Oncology, 2020
View PDFchevron_right
Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanoma
Dace Pjanova
Oncology Letters
View PDFchevron_right
Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma
Janja Ocvirk
Radiology and Oncology
View PDFchevron_right
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research
Parisha Bhatia, Zakaria Elmageed
Annals of translational medicine, 2015
View PDFchevron_right
Molecular alterations in clinical stage�III cutaneous melanoma: Correlation with clinicopathological features and patient outcome
Andrzej Tysarowski
Oncology Letters, 2014
View PDFchevron_right
High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients
Ian Murphy, Joost Van Den Oord
Melanoma Research, 2015
View PDFchevron_right
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
Gabriella Brancaccio
Therapeutic Advances in Medical Oncology, 2020
View PDFchevron_right
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma
Maria Colombino
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012
View PDFchevron_right
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher Risk Primary Melanoma
Stefano Rosso, Marianne Berwick
JAMA oncology, 2015
View PDFchevron_right
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
D. Handolias
2010
View PDFchevron_right
Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study
Zeeshan Zeeshan
Melanoma Management, 2019
View PDFchevron_right
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Janice Mehnert
Current Oncology Reports, 2012
View PDFchevron_right
Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma
KEYUR PATEL
The Journal of Molecular Diagnostics, 2013
View PDFchevron_right
Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients
Marina Pisano
Journal of Clinical Medicine
View PDFchevron_right
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Maria Colombino
2013
View PDFchevron_right
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Ewa Kalinka-Warzocha
New England Journal of Medicine, 2015
View PDFchevron_right
Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
Kristin Leskoske
PLoS ONE, 2012
View PDFchevron_right
Supplementary Figure 1B from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Tunc Iyriboz
2023
View PDFchevron_right
BRAFGene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors
Alessio Fabozzi
Molecular Cancer Therapeutics
View PDFchevron_right
The role of BRAF V600 mutation in melanoma
Ester Simeone
Journal of Translational Medicine, 2012
View PDFchevron_right
Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
Mark Routbort
The Journal of investigative dermatology, 2015
View PDFchevron_right
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
Adil Daud
British Journal of Cancer, 2015
View PDFchevron_right
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
Anna M. Czarnecka
Targeted Oncology, 2023
View PDFchevron_right
Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients
Kayhan Erturk
Neoplasma, 2019
View PDFchevron_right
NRAS mutation status is an independent prognostic factor in metastatic melanoma
Roland Bassett
Cancer, 2012
View PDFchevron_right